期刊
NATURE MEDICINE
卷 10, 期 9, 页码 909-915出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/nm1100
关键词
-
资金
- Intramural NIH HHS [Z01 BC010763-01, Z99 CA999999] Funding Source: Medline
Great progress has been made in the field of tumor immunology in the past decade, but optimism about the clinical application of currently available cancer vaccine approaches is based more on surrogate endpoints than on clinical tumor regression. In our cancer vaccine trials of 440 patients, the objective response rate was low (2.6%), and comparable to the results obtained by others. We consider here results in cancer vaccine trials and highlight alternate strategies that mediate cancer regression in preclinical and clinical models.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据